Last summer, Anirban Maitra, a pathologist specializing in pancreatic cancer, joined the NYU Langone Health Laura and Isaac Perlmutter Cancer Center to co-lead its Gastrointestinal Cancer Center.
Stepping into the NCI director’s job at the end of a nerve-racking year, Anthony Letai wants you to know that the federal government is not going out of the business of cancer research.
Two months into his job as CEO of the American Cancer Society and American Cancer Society Cancer Action Network, Shane Jacobson is still in the drinking-water-from-the-firehose stage of the job.
Richard Pazdur, FDA’s top oncologist who last week received a battlefield promotion to the role of director of the FDA Center for Drug Evaluation and Research, is described as a stabilizing figure respected by major patient groups, oncology professional societies, and the industry.
The first large cancer screening/early detection initiative to be launched in 2025—the NCI-funded Vanguard study of multi-cancer detection tests—has started accruing patients through nine sites across the U.S.
On July 4, President Donald Trump signed into law “The One Big Beautiful Bill Act,” which is expected to deal a massive blow to Medicaid coverage and leave millions without insurance by instituting a work requirement for beneficiaries.
The U.S. Department of Health and Human Services last week cancelled a scheduled meeting of the U.S. Preventive Services Task Force, a 16-member panel that writes guidelines for screening and prevention based on the principles of evidence-based medicine.
For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one […]